Peter Attia MD253 ‒ Hormone replacement therapy and the Women’s Health Initiative: re-examining the results
CHAPTERS
- 0:11 – 7:13
Introduction and JoAnn Manson's h-index
Peter Attia introduces Dr. JoAnn Manson, her credentials, and the episode's focus on the Women's Health Initiative. He also asks her to explain the h-index and notes how high hers ranks.
- •Overview of Manson's roles and research, including the WHI, Nurses' Health Study and VITAL
- •Attia states his bias that HRT fears are overblown
- •Manson explains the h-index as the number of publications with at least that many citations
- •Attia says her h-index of 305 is among the top in biomedical history
- 7:13 – 11:09
Why the WHI Was Launched: Observational Data and Healthy User Bias
Manson describes the 1980s–90s observational studies that linked hormone therapy to lower heart disease and mortality. She explains why a randomized trial was needed to test hormones for chronic disease prevention, a different question from treating hot flashes. Attia raises healthy user bias.
- •Observational studies showed less heart disease, less cognitive decline and lower all-cause mortality in hormone users
- •Clinicians were already prescribing hormones for prevention, even for women decades past menopause
- •Hormone therapy is FDA approved for hot flashes and night sweats, but prevention had never been tested in a randomized trial
- •Confounding by socioeconomic status and health consciousness was a concern
- 11:09 – 16:29
Hormone Formulations Tested and Why
The conversation covers why conjugated equine estrogen with and without medroxyprogesterone acetate were studied, and why women with a uterus need a progestogen. Manson notes that observational participants started hormones earlier than WHI participants, whose average age was 63. They also discuss the history of these formulations and the number of investigators.
- •Estrogen alone is for women with a hysterectomy; women with a uterus need a progestogen to protect the endometrium
- •CEE and MPA were the formulations behind the promising observational findings
- •WHI participants averaged 63, over a decade past menopause
- •One theory is that a pharmaceutical company's dominance explains the use of conjugated estrogens
- •The WHI had about forty principal investigators across clinical centers
- 16:29 – 23:26
Study Design, Eligibility and Participant Characteristics
Manson clarifies who was eligible for the WHI, correcting the misconception that women with hot flashes were excluded. They go through exclusions, age range, prior hormone use, enrollment numbers and the two-trial structure.
- •Women with severe hot flashes often self-selected out, but symptoms did not exclude anyone
- •Women aged 50 to 79 were eligible, with a mean age of 63
- •Prior breast or other estrogen-sensitive cancer and recent cardiovascular events were excluded
- •About 27,000 women were enrolled: roughly 17,000 in estrogen plus progestin and 10,000 in estrogen alone
- •Each trial had its own placebo group with one-to-one randomization
- 23:26 – 27:56
Primary Outcomes, Power and Background Medication Use
They discuss the primary outcomes of coronary heart disease and breast cancer, and what the trial was powered to detect. They also cover statin use during the trial and what was known about oral estrogen and clotting.
- •Coronary heart disease was the primary outcome and breast cancer the primary safety outcome
- •The trial was powered to detect about a 20 percent reduction in heart disease
- •Statin use rose from 7 percent at baseline to over 25 percent during the trial
- •Oral estrogen's effect on clotting proteins and venous thrombosis risk was already understood
- 27:56 – 37:39
Manson's Prior Expectations and Estrogen–Breast Cancer Findings
Manson says she expected only a modest heart benefit at most and suspected confounding in the observational data. They then examine the breast cancer results: increased risk with estrogen plus progestin but not with estrogen alone, and the likely role of MPA.
- •Manson doubted the 40–50% risk reduction would hold up in a trial
- •Mammography surveillance differences could have inflated breast cancer findings in observational studies
- •Estrogen plus progestin raised breast cancer risk by about 25–30%, while estrogen alone showed no increase and later a reduction
- •Both agree the increase with the combination is mostly attributable to MPA
- •Manson says no large trials test micronized progesterone, so caution is prudent
- 37:39 – 41:52
Early Termination and Relative vs. Absolute Risk
They cover why the estrogen plus progestin arm was stopped at 5.6 years and the dropout issues in hormone trials. Attia uses the breast cancer result to illustrate relative versus absolute risk.
- •The arm stopped 3.3 years early because of increased breast cancer, no heart disease reduction and an unfavorable global index
- •Dropout was substantial due to adherence fatigue and side effects
- •A 25% relative increase corresponded to about one extra case per thousand women
- •Estrogen alone showed no significant breast cancer increase at that point and later a reduction
- 41:52 – 52:38
Public Reaction and Misinterpretation of the WHI
Manson describes the shock in the medical community and the sharp drop in hormone therapy use. She distinguishes the appropriate end to prevention use from the inappropriate denial of treatment to symptomatic early-menopausal women. Attia and Manson discuss whether the data support the message that estrogen causes breast cancer.
- •Hormone therapy use fell 70 to 80 percent after the results
- •Stopping prescription for chronic disease prevention in older women was a positive change
- •Extrapolating to symptomatic women in their 40s and 50s was inappropriate
- •Attia argues the study implicates MPA rather than estrogen and showed no mortality difference
- •Manson adds caveats: CEE results may not generalize and biology links estrogen to breast cancer
- 52:38 – 56:00
Individualized Decision-Making and the Swinging Pendulum
Manson stresses shared decision-making, individual risk and emotional well-being, while Attia worries that fear rather than data drives refusals. Manson describes the pendulum swinging from hormones for all women to none, and now toward hormones for some.
- •Benefits and risks vary with age, time since menopause and health status
- •Attia argues fear-based refusal is poorly informed by data
- •Manson says patient anxiety is part of the benefit-risk equation
- •Best candidates are healthy women in early menopause with bothersome symptoms
- 56:00 – 1:03:23
Bone Health, Timing, and Finding a Menopause Clinician
Attia raises reduced hip fractures and the idea that millions of women missed out on benefits. Manson explains why bone benefits fade after stopping, why timing matters, and the age-related signals for heart disease. She also points women to certified menopause practitioners and non-hormonal options.
- •Hip fracture was reduced by about 1.5 percent in absolute terms
- •Bone benefits dissipate within a few years after stopping, and fracture risk peaks decades later
- •Women in their 50s showed favorable signals for heart disease and mortality with estrogen alone
- •North American Menopause Society website helps locate certified practitioners
- •Non-hormonal options such as SSRIs, SNRIs and gabapentinoids reduce hot flashes by 40–50 percent
- 1:03:23 – 1:09:55
Mortality by Age and Long-Term Therapy Thought Experiment
Attia argues that the hip fracture benefit could outweigh breast cancer risk over decades. Manson presents age-stratified mortality data and says no trial has tested 30 years of therapy, noting selection bias in long-term users.
- •Women in their 50s showed signals for about 30% lower mortality, not statistically significant
- •Women 70 to 79 on estrogen alone had a 22% higher mortality hazard, borderline significant
- •Attia's thought experiment suggests a large net mortality benefit from long-term use
- •Manson says long-term benefit-risk is unknown and observational long-term users are a selected group
- •WHI showed increased stroke risk and cognitive decline in women 65 and older
- 1:09:55 – 1:15:54
Modern Formulations and Future Trials
Attia notes that transdermal estradiol and micronized progesterone have replaced CEE and MPA. Manson agrees this is a good trend but says long-term outcomes are unknown, and that a new WHI-scale trial would be expensive and may become obsolete.
- •Transdermal estradiol, micronized progesterone and progesterone IUDs are now common
- •Manson supports preferring them based on clotting and cardiometabolic effects
- •More trials are needed, especially on mammographic breast density
- •A new large trial would require 40,000 to 50,000 women and be very expensive
- •WHI ended preventive use in later menopause but was over-extrapolated to early menopause
- 1:15:54 – 1:20:47
Closing Reflections and Resources
Attia reflects on a lost generation of women denied HRT and praises Manson for acknowledging the WHI's limitations. Manson repeats the key message and the menopause.org resource, followed by outro and show disclosures.
- •Manson repeats where to find a Certified Menopause Practitioner
- •Attia says a generation of women suffered unnecessarily
- •He praises Manson for evolving her thinking on the WHI
- •Closing remarks on membership benefits and disclaimers
